TOKYO/NEW YORK -- The U.S. Food and Drug Administration on Friday approved a treatment for Alzheimer's disease developed by Japanese pharmaceutical company Eisai and American partner Biogen.
Clinical trials showed that lecanemab, which will be marketed as Leqembi, slows cognitive decline for patients in the early stages of Alzheimer's.
